[
    [
        {
            "time": "",
            "original_text": "天坛生物：预计2019年净利润同比增长21%左右",
            "features": {
                "keywords": [
                    "天坛生物",
                    "净利润",
                    "同比增长",
                    "21%",
                    "2019年"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：预计2019年净利润同比增长21%左右",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：预计全年实现净利润6.14亿元，同比增长21%",
            "features": {
                "keywords": [
                    "天坛生物",
                    "净利润",
                    "6.14亿元",
                    "同比增长",
                    "21%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：预计全年实现净利润6.14亿元，同比增长21%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：预计2019年净利6.14亿元 同比增21%",
            "features": {
                "keywords": [
                    "天坛生物",
                    "净利",
                    "6.14亿元",
                    "同比增",
                    "21%",
                    "2019年"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：预计2019年净利6.14亿元 同比增21%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：2019年净利逾6亿元 同比预增21％",
            "features": {
                "keywords": [
                    "天坛生物",
                    "净利",
                    "6亿元",
                    "同比预增",
                    "21%",
                    "2019年"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：2019年净利逾6亿元 同比预增21％",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)2019年度净利预增21%至6.14亿元",
            "features": {
                "keywords": [
                    "天坛生物",
                    "600161.SH",
                    "净利预增",
                    "21%",
                    "6.14亿元",
                    "2019年度"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)2019年度净利预增21%至6.14亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【天风医药 | 专题】2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异",
            "features": {
                "keywords": [
                    "天风医药",
                    "血制品",
                    "批签发",
                    "稳健增长",
                    "因子类产品",
                    "表现优异",
                    "2020年"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "血制品行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药 | 专题】2020年血制品批签发报告：整体批签发稳健增长，因子类产品表现优异",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]